Alto Neuroscience (ANRO) Convertible Debt (2024 - 2026)

Alto Neuroscience has disclosed Convertible Debt across 3 years of filings, most recently posting $2.3 million for Q1 2026.

• Convertible Debt for Q1 2026 came in at $2.3 million, up 92.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 92.82% YoY), and the FY2025 annual result was $2.2 million, up 70.78% from the prior year.
• Convertible Debt came in at $2.3 million for Q1 2026 at Alto Neuroscience, up from $2.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $2.3 million in Q1 2026 to a low of $1.2 million in Q1 2025.
• The 3-year median for Convertible Debt is $2.0 million (2025), against an average of $1.8 million.
• Across the five-year window, Convertible Debt soared 63.64% in 2025 and surged 92.82% in 2026, its largest moves.
• Alto Neuroscience's Convertible Debt stood at $1.3 million in 2024, then soared by 70.78% to $2.2 million in 2025, then grew by 4.85% to $2.3 million in 2026.
• The last three Convertible Debt figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.